Turnover of Medical Products: Market Development Outlook
18 June , 09:30–11:00
Congress Centre, zone B, 2nd floor, conference hall B4
The turnover of medical products includes all stages of the life cycle, from development and production to implementation and use. The challenges of recent years have stimulated the introduction of new domestic drugs on the medical and pharmaceutical markets and the registration of innovative medical products without compromising the safety and quality of products. Issues related to drug supplies are reflected in national projects and experiments. Moreover, the supervisory authorities continue to focus on the quality and safety of medical care.
What are the prospects of an experiment on the traceability of pharmaceutical raw materials? How would a list of strategically important drugs help the domestic industry? What are medical product manufacturers ready to offer the market? What experience would clinicians working with advanced developments like to share? How do innovative technologies help with the rehabilitation of special military operation participants? Does the standardization of processes affect the quality of medical care? What is the outlook for developing the production of high-quality, effective, and safe domestic drugs as part of the country’s efforts to phase out imports? What legislative initiatives concerning the turnover of medical products will ensure the protection of patients' interests?
What are the prospects of an experiment on the traceability of pharmaceutical raw materials? How would a list of strategically important drugs help the domestic industry? What are medical product manufacturers ready to offer the market? What experience would clinicians working with advanced developments like to share? How do innovative technologies help with the rehabilitation of special military operation participants? Does the standardization of processes affect the quality of medical care? What is the outlook for developing the production of high-quality, effective, and safe domestic drugs as part of the country’s efforts to phase out imports? What legislative initiatives concerning the turnover of medical products will ensure the protection of patients' interests?
Panellists
Grachev Nikolay
General Director, Dmitry Rogachev's National Medical Research Center for Pediatric Hematology and Oncology, Ministry of Health of the Russian Federation
Gulenkova Julia
General Director, Ortho-Innovations Moscow
Kabanov Maksim
Head, “Hospital for War Veterans” St. Petersburg State Budgetary Healthcare Institution
Nizharadze Inga
General Director, Skopinpharm
Priezzheva Ekaterina
Deputy Minister of Industry and Trade of the Russian Federation
Shapiro Evgeniya
Director General, PSK Pharma